Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Symposia
Learn more about the planned accredited symposia at the 2026 CDA Annual Conference.
To learn more about planned accredited symposia, check out the details below.
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation
Co-developed with Johnson & Johnson
Taking the Next ‘Step’ in Immune-Mediated Inflammatory Disease: Evaluating Stepwise Care in Canadian Dermatology
They start with a single step, but patient journeys should not feel like a thousand miles. Our symposium will pull from recent surveys, studies, and advocacy efforts to explore patient perceptions and unmet needs in the treatment of their immune-mediated inflammatory diseases. Recent Canadian consensus statements will further inform treatment strategies in those who have yet to start advanced systemic therapy. Discussions by our expert panel will help integrate these perspectives into practice and shared decision-making to strengthen our partnerships with patients. We look forward to seeing you there!
Faculty
Gurbir Dhadwal, MD, FRCPC (Vancouver, BC)
Andrei Metelitsa, MD, FRCPC, DABD (Calgary, AB)
Kerri Purdy, MD, FRCPC (Halifax, NS)
Antonella Scali, CEO – Psoriasis Canada (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Describe patient preferences for oral versus injectable therapies in psoriasis and discuss strategies to incorporate shared decision-making between dermatologists and patients to optimize treatment outcomes.
- Integrate Canadian consensus statements on treatment of moderate-to-severe plaque psoriasis prior to advanced systemic therapy into practice to improve patient care.
- Identify and discuss key unmet needs in psoriasis care from the patient and caregiver perspective, and explore how these findings can inform clinical decision-making and patient-centered treatment strategies.
Co-developed with Novartis Canada
VIP Premiere: Behind the Scenes of CSU Care
Join a multidisciplinary panel of experts, including dermatologists and allergist, for a high-impact symposium addressing the persistent challenges of chronic spontaneous urticaria (CSU) in Canadian practice.
Faculty will examine the burden of CSU, persisting unmet needs, and limitations of current therapies. They will then explore the therapeutic rationale for recently approved and emerging targeted agents, including Bruton’s tyrosine kinase (BTK) inhibitors, connecting these novel mechanisms of action to evolving efficacy and safety data from key clinical trials.
The program will also preview upcoming international CSU guideline updates, helping participants optimize treatment sequencing, personalize care, and confidently integrate new options into everyday Canadian practice.
Faculty
Anne Ellis, MD, MSc, FRCP(C), FAAAAI (Kingston, ON)
Elena Netchiporouk, MD, M.Sc., FRCPC (Montréal, QC)
Maxwell Sauder, MD, FRCPC, FAAD, FCDA (Toronto, ON)
Learning Objectives
At the end of this symposium, participants will be able to:
- Evaluate the burden of chronic spontaneous urticaria (CSU) in Canada, highlighting unmet needs, treatment gaps, and limitations of current therapies.
- Explain the pathogenesis of CSU and the therapeutic rationale for emerging targeted agents, linking mechanism of action to efficacy and safety.
- Integrate international CSU guideline updates (anticipated 2026) with emerging clinical trial data to optimize treatment sequencing and positioning of new therapies in Canadian practice.
Co-developed with AbbVie Corporation